Treatment of aplastic anemia with combined immunnosupprression: antithymocyte globulin (ATG), cyclosporine A (CsA), and mycophenolate mofetil (MMF)

Description:For patients with newly diagnosed aplastic anemia, not previously treated by immunosuppression, we offer entry to a pilot phase II study which combines antithymocyte globulin, cyclosporine, and a new drug, mycophenolate mophetil. This therapy appears to have lower toxicity than conventional immunosuppression and at least as high a response rate. This phase II study require 2 to 3 weeks hospitalization.

Inclusion Criteria:

Only patients with SAA will be admitted, defined as:
bone marrow cellularity <30%

at least two of the following blood count findings:

absolute granulocyte count < 500/mm3

platelet count <20, 000/mm3

reticulocyte count < 60, 000/mm3